PixCell Medical's HemoScreen CBC Analyzer Achieves IVDR Certification--A Game-Changer for Point-of-Care Diagnostics

YOKNEAM ILIT, Israel, Nov. 27, 2024 /PRNewswire/ -- PixCell Medical, a leading innovator in point-of-care diagnostics, proudly announces that its groundbreaking HemoScreen CBC analyzer has achieved certification under the In Vitro Diagnostic Medical Devices Regulation (IVDR) (EU) 2017/746. As the only FDA-cleared, point-of-care 5-part differential Complete Blood Count (CBC) analyzer, HemoScreen is now also the first device of its kind to meet the stringent IVDR requirements. This dual milestone cements PixCell Medical's position as a pioneer in advancing patient care through rapid, accurate, and portable diagnostic solutions.

By securing IVDR certification years ahead of the regulatory deadline, HemoScreen reaffirms PixCell Medical's proactive commitment to quality, safety, and innovation. The rigorous certification process validated the analyzer's clinical performance, safety, and reliability across diverse healthcare settings, underscoring its role as a lab-accurate diagnostic tool at the point of care.

Dr. Avishay Bransky, CEO of PixCell Medical, remarked: "Achieving IVDR certification for HemoScreen is more than a regulatory milestone—it's a validation of our mission to transform diagnostics at the point of care. By meeting the strictest regulatory standards in both the EU and the US, we're ensuring that healthcare providers worldwide have access to reliable, innovative tools that enhance patient care."

PixCell Medical's IVDR certification process was conducted by Dekra, its EU Notified Body, and involved thorough evaluations of clinical evidence, performance data, and post-market surveillance standards. The certification confirms HemoScreen's compliance with the highest industry benchmarks for safety and efficacy.

About PixCell Medical
PixCell Medical, an innovator of rapid hematology testing solutions at the point-of-care, has developed the only 5-part differential Complete Blood Count (CBC) analyzer that is FDA-cleared for point-of-care use – the HemoScreen™.

HemoScreen enables healthcare providers to perform rapid, high-quality CBC testing with just a single drop of blood and minimal training. Its patented disposable cartridges, preloaded with reagents, combined with AI-powered machine vision and Viscoelastic Focusing technology, make it uniquely suited for decentralized medical environments such as clinics, emergency rooms, and remote locations.

For more information: www.pixcell-medical.com
Follow PixCell Medical on LinkedIn and Twitter.

Logo - https://mma.prnewswire.com/media/1501459/3647235/PixCell_Medical_Logo.jpg

Media Contact:
PixCell Medical
Jake Jones
[email protected]